Acadia closes on $150M FDA voucher sale
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
Grandbrothers Acadia Pharmaceuticals (NASDAQ:ACAD) said it has closed on the sale of its FDA Rare
ACAD
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
by Terry Chrisomalis
Contributor since 2013 / 12985 Followers
Contributor since 2013 / 12985 Followers
4 weeks ago
Summary: NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is
Acadia signs licensing deal for essential tremor drug candidate
by
Contributor since / Followers
Contributor since / Followers
4 weeks ago
designer491/iStock via Getty Images Acadia Pharmaceuticals (NASDAQ:ACAD) has entered into an exclusive global licensing deal
Acadia Pharmaceuticals: Proving The Naysayers Wrong
by Bret Jensen
Contributor since 2010 / 50459 Followers
Contributor since 2010 / 50459 Followers
1 month ago
Summary: Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some
Acadia Pharma GAAP EPS of $0.20 beats by $0.06, revenue of $250.4M beats by $1.56M
by
Contributor since / Followers
Contributor since / Followers
2 months ago
Acadia Pharma press release (NASDAQ:ACAD): Q3 GAAP EPS of $0.20 beats by $0.06. Revenue of
Acadia Pharma Q3 2024 Earnings Preview
by
Contributor since / Followers
Contributor since / Followers
2 months ago
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q3 earnings results on Wednesday, November 6th, after
Acadia sells Rare Pediatric Disease Priority Review Voucher for $150M
by
Contributor since / Followers
Contributor since / Followers
2 months ago
hapabapa Acadia Pharmaceuticals (NASDAQ:ACAD) has sold a Rare Pediatric Disease Priority Review Voucher for $150M.
Catherine Owen appointed as CEO of Acadia Pharmaceuticals
by
Contributor since / Followers
Contributor since / Followers
3 months ago
Acadia Pharmaceuticals (NASDAQ:ACAD) announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
by ONeil Trader
Contributor since 2012 / 8517 Followers
Contributor since 2012 / 8517 Followers
4 months ago
Summary: Shares of Acadia trended lower this year due to Daybue’s poor quarterly sales performance,
ACADIA Pharma cut at Morgan Stanley on Daybue miss
by
Contributor since / Followers
Contributor since / Followers
5 months ago
LeoPatrizi Despite ACADIA Pharmaceuticals’ (NASDAQ:ACAD) Q2 beat yesterday, Morgan Stanley downgraded the stock on Wednesday,